BioNTech Achieves Major Oncology Breakthrough with Phase 3 Cancer Trial Success

German biotechnology firm BioNTech has announced a significant advancement in its oncology pipeline, marking a pivotal achievement beyond its renowned COVID-19 vaccine work. The company reported positive topline results from a Phase 3 trial for its cancer drug candidate BNT323/DB-1303, developed in collaboration with Chinese partner DualityBio.

The trial investigated the efficacy of BNT323/DB-1303, an antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer who had undergone prior treatments. Conducted in China, the study met its primary endpoint of progression-free survival at a pre-planned interim analysis. The therapeutic agent is designed to specifically target the HER2 protein, a recognized driver of tumor growth.

This development represents BioNTech’s first late-stage success in oncology since shifting significant Read more...